Mexican President Claudia Sheinbaum Pardo highlighted the more than 21 billion pesos in investments announced by several pharmaceutical companies as part of Plan México, a strategy aimed at increasing domestic medicine production, strengthening the industry, and expanding exports in the sector.
During “Las mañaneras del pueblo,” the president thanked the companies for their confidence in the country and emphasized that the goal of the plan is to produce in Mexico the medicines consumed by the population, while also consolidating the nation as an export platform for international markets.
Health Secretary David Kershenobich Stalnikowitz stated that these investments will boost industrial and healthcare development through projects focused on clinical research, local manufacturing, and the expansion of pharmaceutical infrastructure in different regions of the country.
Among the announced investments are 5.36 billion pesos from Laboratorios Kener; 4 billion pesos from Liomont; 3.5 billion pesos from ABBOTT; 2.3 billion pesos from Opella; more than 2 billion pesos from Sanofi; 1 billion pesos from Bristol Myers Squibb; 750 million pesos from Grupo Neolpharma; as well as new investments from Bayer in clinical studies and pharmaceutical development.
The companies reported that the projects include the construction and expansion of production plants, the manufacturing of vaccines, medicines, and medical supplies, as well as the creation of thousands of direct and indirect jobs in states such as the State of Mexico, Querétaro, and Mexico City, strengthening healthcare sovereignty and access to treatments for the population.
